Benchmark (AIM: BMK), an established international animal health, technical publishing and sustainability science business, is pleased to announce that its shares will today be admitted to trading on AIM.
In an oversubscribed fundraising led by Cenkos Securities and supported by Equity Development, Benchmark has successfully raised £27.5 million before expenses through the sale of new ordinary shares at a price of 64 pence per share to a diverse range of investors. In addition, existing shareholders have sold shares worth £17.6 million. Total gross proceeds from the placing amounted to £45.1 million, making this the largest fundraising in the healthcare sector this year on AIM. At admission, the Company will have a total of 136,416,750 ordinary shares in issue.
The proceeds of the fundraising will be used by Benchmark to invest in high quality scientific research and development, to enhance its business development team, to expand its core businesses and enter into new segments which fit synergistically with its existing businesses. The proceeds will also be used to fund the expansion of Benchmark's manufacturing base, as well as selective acquisitions.
http://www.investegate.co.uk/benchmark-hlgs-plc--bmk-/rns/admission-and-first-day-of-dealings-on-aim/201312180800028049V/
FUNDIES
Latest Share Price (p) 122.50 Net Gearing (%) n/a
Market Cap (£m) 167.11 Gross Gearing (%) n/a
Shares in issue (m) 136.42 Debt Ratio n/a
P/E Ratio 0.00 Debt-to-Equity Ratio n/a
Divs per share (p) n/a Assets / Equity Ratio n/a
Dividend Yield (%) 0.00 Price to book value n/a
Dividend Cover 0.00 ROCE n/a
Earning per share (p) 0.00 EPS Growth (%) n/a
52-week high / low (p) 122.50 / 67.00 DPS Growth (%) n/a